189
the intraocular tissue distribution, pharmacokinetics, and safety of
125I-labeled full-length and Fab antibodies in rhesus monkeys fol-
lowing intravitreal administration. Toxicol Pathol 1999;27:536–44.
90. Mordenti J, Thomsen K, Licko V, et al. Intraocular pharmacoki-
netics and safety of a humanized monoclonal anti-body in rabbits
after intravitreal administration of a solution or a PLGA micro-
sphere formulation. Toxicol Sci 1999;52:101– 6.
91. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevaci-
zumab (Avastin) for neovascular age-related macular degeneration.
Ophthalmology 2006;113:363–72.
92. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the
treatment of ocular disease. Surv Ophthalmol. 2009 May-
Jun;54(3):372-400.
93. Emerson MV, Lauer AK, Flaxel CJ, et al. Intravitreal bevacizumab
(Avastin) treatment of neovascular age-related macular degenera-
tion. Retina 2007;27:439–44.
94. Goff MJ, Johnson RN, McDonald HR, et al. Intravitreal beva-
cizumab for previously treated choroidal neovascularization from
age-related macular degeneration. Retina 2007; 27:432–8.
95. Spaide RF, Laud K, Fine JFF, et al. Intravitreal bevacizumab treat-
ment of choroidal neovascularization secondary to age-related
macular degeneration. Retina. 2006; 26:383—90
96. Yoganathan P, Deramo VA, Lai JC, et al. Visual improvement fol-
lowing intravitreal bevacizumab (Avastin) in exudative age-related
macular degeneration. Retina. 2006; 26:994—8.
97. Ehrlich R, Weinberger D, Priel E, Axer-Siegel R. Outcome of be-
vacizumab (avastin) injection in patients with agerelated macular
degeneration and low visual acuity. Retina. 2008; 28(9):1302—7.
98. Grisanti S, Ziemssen F. Bevacizumab: off-label use in ophthalmol-
ogy. Indian J Ophthalmol. 2007 Nov-Dec;55(6):417-20.
99. Wu L, Martinez-Castellanos MA, Quiroz-Mercado H, et al. for the
Pan American Collaborative Retina Group (PACORES). Twelve-
month safety of intravitreal injections of bevacizumab (Avastin):
results of the Pan-American Collaborative Retina Study Group (PA-
CORES). Graefes Arch Clin Exp Ophthalmol. 2008; 246(1):81—7.
100.Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea C,
Loukianou E, Moschos M. Intravitreal use of bevacizumab (Avas-
tin) for choroidal neovascularization due to ARMD: A preliminary
multifocal-ERG and OCT study: Multifocal-ERG after use of be-
vacizumab in ARMD. Doc Ophthalmol. 2007;114:37–44.
101.Spitzer MS, Yoeruek E, Sierra A, Wallenfels-Thilo B, Schraer-
meyer U, Spitzer B, Bartz-Schmidt KU, Szurman P. Comparative
antiproliferative and cytotoxic profile of bevacizumab (Avastin),
pegaptanib (Macugen) and ranibizumab (Lucentis) on differ-
ent ocular cells. Graefes Arch Clin Exp Ophthalmol. 2007 Dec;
245(12):1837-42. Epub 2007 Mar 9.
102.Luke M, Warga M, Ziemssen F, Gelisken F, Grisanti S, Schneider
T, et al. Effects of bevacizumab on retinal function in isolated ver-
tebrate retina. Br J Ophthalmol. 2006;90:1178–82.
103.Manzano RP, Peyman GA, Khan P, Kivilcim M. Testing intravit-
real toxicity of bevacizumab (Avastin). Retina. 2006;26:257–61.
104.Luthra S, Narayanan R, Marques LE, Chwa M, Kim DW, Dong
J, et al. Evaluation of in vitro effects of bevacizumab (Avastin) on
retinal pigment epithelial, neurosensory retinal and microvascular
endothelial cells. Retina. 2006;26:512–8.
105.Feiner L, Barr EE, Shui YB, Holekamp NM, Brantley MA., Jr
Safety of intravitreal injection of bevacizumab in rabbit eyes. Reti-
na. 2006;26:882–8.
106.Inan UU, Avci B, Kusbeci T, Kaderli B, Avci R, Temel SG. Pre-
clinical safety evaluation of Intravitreal injection of full-length
humanized vascular endothelial growth factor antibody in rabbit
eyes. Invest Ophthalmol Vis Sci. 2007; 48:1773–81.
107.Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab
(Avastin) therapy for neovascular age-related macular degeneration
twelve-week results of an uncontrolled open-label clinical study.
Ophthalmology. 2005; 112(6):1035—47.
108.Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic be-
vacizumab (Avastin) therapy for neovascular age-related macular
degeneration: twenty-four-week results of an uncontrolled open-
label clinical study. Ophthalmology. 2006;113(11):1—12.
109.American Society of Retina Specialists. Preferences And Trends
Survey. Palm Springs, CA 2007.
Anti-VEGF in the treatment of AMD
